Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 7/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HINT1 | P49773 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22216550 | 0.91 | ADORA3 (0.54) | LMNARXFP1ADORA3NT5EADORA2A | |
| SCHEMBL6936922 | 0.91 | ADORA3 (0.51) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL8594450 | 0.91 | AHCY (0.50) | STING1LMNAADORA3NT5EADORA2A | |
| SCHEMBL19961896 | 0.91 | ADORA3 (0.54) | LMNARXFP1ADORA3NT5EADORA2A | |
| SCHEMBL4757808 | 0.91 | ADORA3 (0.54) | LMNARXFP1ADORA3NT5EADORA2A | |
| SCHEMBL13030116 | 0.91 | NT5E (0.43) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL10238968 | 0.90 | SLC29A1 (0.39) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL15763461 | 0.89 | SLC29A1 (0.39) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL22983991 | 0.88 | STING1 (0.56) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL6895355 | 0.88 | STING1 (0.56) | STING1LMNAKMT2ARAPGEF3GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972330-B2 | Contacting N4-acetyl-5',3'-di-O-acetyl-2'-O- methyl cytidine with Lewis acid to form 2'-)-methyladenosine nucleoside which is converted to phosphoramidite | SIRNA THERAPEUTICS, INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | claimed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | claimed |
| US-5962675-A | Chemical syntheses of 2'-O-methoxy purine nucleosides | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | claimed |
| EP-0886641-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-30 | — | — | EP | claimed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | claimed |
| US-7101993-B1 | Oligonucleotides containing 2′-O-modified purines | ISIS PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-6972330-B2 | Contacting N4-acetyl-5',3'-di-O-acetyl-2'-O- methyl cytidine with Lewis acid to form 2'-)-methyladenosine nucleoside which is converted to phosphoramidite | SIRNA THERAPEUTICS, INC. (US) | 2005-12-06 | — | — | US | disclosed |
| EP-1223173-B1 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | ISIS PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | disclosed |
| EP-0651759-B1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS INC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1223173-A2 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6242592-B1 | Process for the preparation of 2′-O-alkyl-guanosine, cytidine, and uridine phosphoramidites | ISIS PHARMACEUTICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| US-6133438-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-5962675-A | Chemical syntheses of 2'-O-methoxy purine nucleosides | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5914396-A | 2'-O-modified nucleosides and phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5856466-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | UMPS, PNP, NUDT1 | STING1 1716/4885HSP90B1 2733/4885LMNA 1006/4885 |
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | NSUN2, RNMT, HNRNPL | STING1 1230/4885HSP90B1 4063/4885LMNA 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.